AI Agent

3

Review clinical trials related to AI Agent. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Multi-Theory Model-Based AI Agent Intervention for Smoking Cessation in Early-Stage Cancer Patients

The goal of this clinical trial is to evaluate the effectiveness of a Multi-Theory Model (MTM)-based AI agent intervention for smoking cessation in early-stage cancer patients (clinical stage cTNM 0\~II) who currently smoke. The main questions it aims to answer are: Does the AI agent intervention improve the biochemically verified 7-day point prevalence abstinence rate at the 6-month follow-up compared to control groups? Is the AI agent intervention feasible and acceptable for early-stage cancer patients? Researchers will compare the AI agent intervention group to an professional counseling group and a routine health education groupto see if the AI agent yields higher smoking cessation rates and better maintenance of abstinence. Participants will: Be randomly assigned to one of three groups to receive either AI agent support via WeChat, professional counseling via Phone, or routine health education. Interact with the AI agent (if in the intervention group) which provides personalized guidance, emotional support, and resource matching based on the Multi-Theory Model constructs (e.g., participatory dialogue, emotional transformation). Complete questionnaires regarding smoking behavior, nicotine dependence, self-efficacy, and quality of life at baseline and follow-ups (1 week, 1 month, 3 months, and 6 months). Provide exhaled carbon monoxide (CO) and saliva cotinine samples for biochemical verification if they report successful smoking cessation.

Participants needed: 156
Trial details
Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Sep 18, 2026
Eligibility criteria

Age ≥18 years, diagnosed with early-stage cancer (AJCC 8th edition clinical stag... [+4]

Individuals who are unable to communicate due to severe mental or physical illne... [+2]

Status: Not yet recruiting

A Multimodal AI Agent for Ophthalmic Clinical Decision Support

This study is a multicenter randomized controlled trial evaluating the effectiveness and safety of EyeAgent, a multimodal artificial intelligence (AI) agent designed to assist ophthalmologists in clinical decision-making. Participants will be recruited from ophthalmology clinics and hospitals in Hong Kong and mainland China. The AI agent acts as a digital co-pilot, analyzing patient images and clinical history to provide diagnostic and management recommendations. The trial aims to determine whether the use of the AI agent improves diagnostic accuracy, treatment decision-making performance, report generation, workflow efficiency, and user satisfaction compared to standard clinical practice.

Participants needed: 300
Trial details
Age: 6-75Biological sex: AllType: InterventionalSponsor: The Hong Kong Polytechnic UniversityUpdated: Feb 23, 2026Locations: 1
Eligibility criteria

Outpatient participants aged 6 to 75 years. [+4]

Participants who are reluctant to participate in this study. [+3]

Status: Recruiting

AI-Agent for Automated Diagnosis and Predicting Using EHR and Multimodal Data

The goal of this clinical study is to evaluate the effectiveness of an AI agent in diagnosing and predicting diseases using electronic health records (EHR) and multimodal imaging data. The AI agent leverages advanced machine learning algorithms to process and analyze diverse health data sources, aiming to assist healthcare providers in making more accurate diagnoses and predictions.

Participants needed: 2,000,000
Trial details
Biological sex: AllType: ObservationalSponsor: The Eye Hospital of Wenzhou Medical UniversityUpdated: Apr 17, 2025Locations: 6
Eligibility criteria

Participants must have comprehensive electronic health records (EHR) available,... [+3]

Participants with ambiguous or unverifiable diagnoses that cannot be accurately... [+1]